https://www.selleckchem.com/pr....oducts/Staurosporine
Median follow up was 4.9 months. The overall survival for the entire cohort was 5.2 months. On Cox regression predictors of improved survival were receipt of chemotherapy, no extracranial disease, and SRS. After propensity matching, median survival was 8.3 months compared to 6.3 months in favor of SRS. Conclusions This study represents the largest series to date of patients with brain metastases from gynecologic malignancies, confirming an incidence of less then 1% and overall poor prognosis. Radiation remains a viable treatment o
Like
Comment
Share
